New drug duo targets Tough-to-Treat penile cancer
NCT ID NCT07110038
Summary
This study is testing a new combination of two existing drugs, enfortumab vedotin and avelumab, as a first treatment for men with advanced penile cancer that has spread or cannot be removed by surgery. The main goal is to see how well the combination shrinks tumors and controls the disease. Researchers will also track how long patients live, side effects, and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PENILE SQUAMOUS CELL CARCINOMA (PSCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Mannheim
RECRUITINGMannheim, Germany
-
University Hospital Tübingen
RECRUITINGTübingen, Germany
Contact
Conditions
Explore the condition pages connected to this study.